Responsibility in Drug Advertising Act of 2025
Responsibility in Drug Advertising Act of 2025
Plain Language Summary
# Responsibility in Drug Advertising Act of 2025 – Plain Language Summary **What the Bill Does:** This bill would prevent pharmaceutical companies from advertising new prescription drugs directly to consumers (through TV, social media, websites, etc.) for the first three years after the FDA approves them. The main goal is to give regulators and doctors time to gather real-world safety information before companies market drugs to the general public. After three years, companies could advertise unless the FDA finds serious health risks, or they could request early permission to advertise in year three if the FDA agrees it would benefit public health. **Who It Affects:** This primarily affects pharmaceutical companies, patients, and healthcare providers. Drug companies would face restrictions on their marketing strategies for new medications.
Patients and consumers would see fewer advertisements for newly approved drugs during the initial period. Healthcare providers might have more control over the conversation about new treatment options before direct-to-consumer advertising begins. **Current Status:** The bill was introduced by Representative Rosa DeLauro (D-CT) and is currently in committee, meaning it hasn't yet been debated or voted on by the full House of Representatives. It would apply to drugs approved starting one year before the bill becomes law (if it passes).
CRS Official Summary
Responsibility in Drug Advertising Act of 2025This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media. Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources. The prohibition applies to new drugs approved beginning one year before the bill’s enactment.
Latest Action
Referred to the House Committee on Energy and Commerce.